Melina Marmarelis, MD, Thoracic Medical Oncologist, UPenn joins us for an interview about precision medicine. She discusses biomarker information, such as histology (currently most valuable), but also molecular testing such as NF2, MTAP, CDKN2A mutations that can be used when determining precision medicine treatments. Other topics discussed are BAP1 mutations, PDL1 expression, mutational burden, and oncolytic viruses.
The interview is moderated by Julie White, BSN, OCN, RN who is the patient services director at the Mesothelioma Applied Research Foundation. More information is available at curemeso.org.
26 фев 2024
